In contrast to the JAK2V617F mutation, which is a single amino acid change, mutant CALR protein represents a large neoantigen that is expressed on the cell surface, and therefore is an attractive target for tumour‐specific immunotherapy in patients with mutCALR‐driven MPN. Here, CALR is linked to myeloproliferative neoplasm.